ABIOMED, Inc. (NASDAQ:ABMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ABIOMED, Inc. (NASDAQ:ABMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

On March 22, 2019, after 37 years of service, William J. Bolt announced he will retire from his position as Senior Vice President, Regulatory and Clinical Programs of ABIOMED, Inc. (the “Company”).Effective April 1, 2019, Mr. Bolt will begin transitioning out of his current role and will cease serving as an executive officer of the Company when he retires on May 31, 2019.

About ABIOMED, Inc. (NASDAQ:ABMD)

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company’s product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company’s products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

An ad to help with our costs